A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...

Positive topline results from the phase 3 GLOW2 trial suggest that tarcocimab tedromer (Zenkuda), an investigational anti–vascular endothelial growth factor (VEGF) biologic, may offer durable disease ...

Chemical injuries to the ocular surface can be challenging to manage because they lie at the intersection of urgency and long-term consequences. The severity of these injuries dep ...

ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...

In this episode of “iOpeners” from Ophthalmology Times, host Nicole Bajic, MD, comprehensive ophthalmologist at the Cole Eye Institute, Cleveland Clinic, speaks with Emily Schehlein, MD, about efforts ...

In unilateral intermittent exotropia, distance control improved significantly over 3 months of therapy (mean 2.9 to 1.7; ...

Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...

Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...

Lineage’s COR1 targets restoration of endothelial pump function via intracameral delivery and adhesion to Descemet membrane, ...

BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...